Government-Owned Inventions; Availability for Licensing, 58949-58950 [2016-20444]
Download as PDF
<![CDATA[
Federal Register / Vol. 81, No. 166 / Friday, August 26, 2016 / Notices
mstockstill on DSK3G9T082PROD with NOTICES
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; NIDDK Ancillary
Studies.
Date: September 9, 2016.
Time: 2:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Elena Sanovich, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7351, 6707 Democracy Boulevard,
Bethesda, MD 20892–2542, 301–594–8886,
sanoviche@mail.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; NIDDK DEM
Fellowship Grant Applications Review.
Date: October 3, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Carol J. Goter-Robinson,
Ph.D., Scientific Review Officer, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 7347, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
594–7791, goterrobinsonc@
extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; PAR–15–067:
NIDDK Multi-Center Clinical Study
Cooperative Agreement (U01).
Date: October 3, 2016.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Dianne Camp, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7013, 6707 Democracy Boulevard,
Bethesda, MD 20892–2542, 301–594–7682,
campd@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; RFA–DK–16–002:
Understanding Barriers and Facilitators to
Type 1 Diabetes Management in Adults.
Date: October 6, 2016.
Time: 1:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Dianne Camp, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7013, 6707 Democracy Boulevard,
VerDate Sep<11>2014
21:17 Aug 25, 2016
Jkt 238001
Bethesda, MD 20892–2542, 301–594–7682,
campd@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; The NIDDK–KUHFellowship Review SEP.
Date: October 7, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Kinzie Hotel, 20 W Kinzie Street,
Chicago, IL 60654.
Contact Person: Xiaodu Guo, MD, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7023, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–4719,
guox@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; The NIDDK–DDK–D
Member Conflict SEP.
Date: October 7, 2016.
Time: 9:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Kinzie Hotel, 20 W Kinzie Street,
Chicago, IL 60654.
Contact Person: Xiaodu Guo, MD, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7023, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–4719,
guox@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: August 22, 2016.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–20445 Filed 8–25–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing and/or co-development in the
U.S. in accordance with 35 U.S.C. 209
and 37 CFR part 404 to achieve
expeditious commercialization of
results of federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
SUMMARY:
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
58949
for companies and may also be available
for licensing and/or co-development.
ADDRESSES: Invention Development and
Marketing Unit, Technology Transfer
Center, National Cancer Institute, 9609
Medical Center Drive, Mail Stop 9702,
Rockville, MD 20850–9702.
FOR FURTHER INFORMATION CONTACT:
Information on licensing and codevelopment research collaborations,
and copies of the U.S. patent
applications listed below may be
obtained by contacting: Attn. Invention
Development and Marketing Unit,
Technology Transfer Center, National
Cancer Institute, 9609 Medical Center
Drive, Mail Stop 9702, Rockville, MD
20850–9702, Tel. 240–276–5515 or
email ncitechtransfer@mail.nih.gov. A
signed Confidential Disclosure
Agreement may be required to receive
copies of the patent applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Title of invention:
Detection of Colorectal Cancer Using
Two Heme-Related Molecules in Human
Feces.
Description of Technology:
Mortality from colorectal cancer
(CRC) can be reduced by detecting the
cancer or its precursor, colorectal
adenoma (CRA), so that it can be
removed at an early stage. Current tests
involve screening stool specimens for
blood, especially for hemoglobin. The
fecal immunochemical test (FIT) for
hemoglobin is positive in stool for about
60% of early-stage and 85% of advanced
CRC cases, with a false-positive rate of
less than 10%. Assays with better
accuracy are still needed.
The subject technology is a novel
assay that detects the presence or
absence of one or both of two hemerelated peptides, X–18565 and X–19549
in stool samples. The presence of one,
and especially both, of these peptides
within the stool sample indicates a high
likelihood that CRC or CRA is present
within the patient. X–18565 was
detected in 67% of CRC cases and the
specificity of X–18565 was 99%, as it
was detected in only 1% of control
patients who did not have CRC (e.g.,
false positives). X–19549 was detected
in 48% of CRC cases and the specificity
of X–19549 was 97%, as it was detected
in only 3% of controls patients who did
not have CRC (e.g., false positives). The
absence of both X–18565 and X–19549
from the stool sample (or extract)
indicates a greater than 95% likelihood
that CRC or CRA is not present within
the patient from which the stool sample
is obtained. The assay can be performed
on fresh or frozen samples.
E:\FR\FM\26AUN1.SGM
26AUN1
58950
Federal Register / Vol. 81, No. 166 / Friday, August 26, 2016 / Notices
Potential Commercial Applications:
• Diagnostic for colorectal cancer.
Value Proposition:
• Assay has high specificity.
• Fresh and frozen samples can be
utilized by this assay.
Development Stage:
Pre-clinical (in vivo validation).
Inventor(s):
James J. Goedert (NCI) and Rashmi
Sinha (NCI).
Intellectual Property:
HHS Reference No. E–198–2014/0–
PCT–02.
International PCT Application No.
PCT/US2015/038299 (HHS Reference
No. E–198–2014/0–PCT–02) filed June
29, 2015 entitled, ‘‘Detection of
Colorectal Cancer with Two Novel
Heme-Related Molecules in Human
Feces.’’
Publications:
1. J.J. Goedert et al. Fecal Metabolomics:
Assay Performance and Association
with Colorectal Cancer.
Carcinogenesis. 2014 Sep;35(9):2089–
96. [PMID: 25037050].
Collaboration Opportunity
The NCI seeks licensing or codevelopment collaborations the would
enable eventual commercialization of
the diagnostic technology.
Contact Information
Requests for copies of the patent
application or inquiries about licensing,
research collaborations, and codevelopment opportunities should be
sent to John D. Hewes, Ph.D., email:
john.hewes@nih.gov.
Dated: August 17, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology
Transfer Center, National Cancer Institute.
[FR Doc. 2016–20444 Filed 8–25–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
mstockstill on DSK3G9T082PROD with NOTICES
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Advisory Council for
Biomedical Imaging and Bioengineering.
The meeting will be open to the
public as indicated below, with
VerDate Sep<11>2014
21:17 Aug 25, 2016
Jkt 238001
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council for Biomedical Imaging and
Bioengineering.
Date: September 15, 2016.
Open: 8:30 a.m. to 12:00 p.m.
Agenda: Report from the Institute Director,
other Institute Staff and scientific
presentation.
Place: The William F. Bolger Center,
Franklin Building, Classroom 15/16, 9600
Newbridge Drive, Potomac, MD 20854.
Closed: 1:30 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: The William F. Bolger Center,
Franklin Building, Classroom 15/16, 9600
Newbridge Drive, Potomac, MD 20854.
Contact Person: David T. George, Ph.D.,
Acting Associate Director, Office of Research
Administration, National Institute of
Biomedical Imaging, and Bioengineering,
6707 Democracy Boulevard, Room 920,
Bethesda, MD 20892.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
www.nibib1.nih.gov/about/NACBIB/
NACBIB.htm, where an agenda and any
additional information for the meeting will
be posted when available.
Dated: August 22, 2016.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–20437 Filed 8–25–16; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Zika R21 Rapid Review.
Date: September 21, 2016.
Time: 1:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Room 7189, Bethesda, MD
20892, (Telephone Conference Call).
Contact Person: Stephanie L Constant,
Ph.D., Scientific Review Officer, Office of
Scientific Review/DERA, National Heart,
Lung, and Blood Institute, 6701 Rockledge
Drive, Room 7189, Bethesda, MD 20892, 301–
443–8784, constantsl@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: August 22, 2016.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–20438 Filed 8–25–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
E:\FR\FM\26AUN1.SGM
26AUN1
]]>Agencies
[Federal Register Volume 81, Number 166 (Friday, August 26, 2016)]
[Notices]
[Pages 58949-58950]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-20444]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing and/or co-development in the
U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve
expeditious commercialization of results of federally-funded research
and development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing and/or co-development.
ADDRESSES: Invention Development and Marketing Unit, Technology
Transfer Center, National Cancer Institute, 9609 Medical Center Drive,
Mail Stop 9702, Rockville, MD 20850-9702.
FOR FURTHER INFORMATION CONTACT: Information on licensing and co-
development research collaborations, and copies of the U.S. patent
applications listed below may be obtained by contacting: Attn.
Invention Development and Marketing Unit, Technology Transfer Center,
National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702,
Rockville, MD 20850-9702, Tel. 240-276-5515 or email
ncitechtransfer@mail.nih.gov. A signed Confidential Disclosure
Agreement may be required to receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows.
Title of invention:
Detection of Colorectal Cancer Using Two Heme-Related Molecules in
Human Feces.
Description of Technology:
Mortality from colorectal cancer (CRC) can be reduced by detecting
the cancer or its precursor, colorectal adenoma (CRA), so that it can
be removed at an early stage. Current tests involve screening stool
specimens for blood, especially for hemoglobin. The fecal
immunochemical test (FIT) for hemoglobin is positive in stool for about
60% of early-stage and 85% of advanced CRC cases, with a false-positive
rate of less than 10%. Assays with better accuracy are still needed.
The subject technology is a novel assay that detects the presence
or absence of one or both of two heme-related peptides, X-18565 and X-
19549 in stool samples. The presence of one, and especially both, of
these peptides within the stool sample indicates a high likelihood that
CRC or CRA is present within the patient. X-18565 was detected in 67%
of CRC cases and the specificity of X-18565 was 99%, as it was detected
in only 1% of control patients who did not have CRC (e.g., false
positives). X-19549 was detected in 48% of CRC cases and the
specificity of X-19549 was 97%, as it was detected in only 3% of
controls patients who did not have CRC (e.g., false positives). The
absence of both X-18565 and X-19549 from the stool sample (or extract)
indicates a greater than 95% likelihood that CRC or CRA is not present
within the patient from which the stool sample is obtained. The assay
can be performed on fresh or frozen samples.
[[Page 58950]]
Potential Commercial Applications:
Diagnostic for colorectal cancer.
Value Proposition:
Assay has high specificity.
Fresh and frozen samples can be utilized by this assay.
Development Stage:
Pre-clinical (in vivo validation).
Inventor(s):
James J. Goedert (NCI) and Rashmi Sinha (NCI).
Intellectual Property:
HHS Reference No. E-198-2014/0-PCT-02.
International PCT Application No. PCT/US2015/038299 (HHS Reference
No. E-198-2014/0-PCT-02) filed June 29, 2015 entitled, ``Detection of
Colorectal Cancer with Two Novel Heme-Related Molecules in Human
Feces.''
Publications:
1. J.J. Goedert et al. Fecal Metabolomics: Assay Performance and
Association with Colorectal Cancer. Carcinogenesis. 2014
Sep;35(9):2089-96. [PMID: 25037050].
Collaboration Opportunity
The NCI seeks licensing or co-development collaborations the would
enable eventual commercialization of the diagnostic technology.
Contact Information
Requests for copies of the patent application or inquiries about
licensing, research collaborations, and co-development opportunities
should be sent to John D. Hewes, Ph.D., email: john.hewes@nih.gov.
Dated: August 17, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology Transfer Center, National
Cancer Institute.
[FR Doc. 2016-20444 Filed 8-25-16; 8:45 am]
BILLING CODE 4140-01-P
